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 Abstract 
  Background/Aims:   In this post-marketing observational study, the safety and effectiveness of 
memantine were evaluated in patients with Alzheimer’s disease (AD).   Methods:   In a 6-month, 
observational, open-label study at 202 specialist sites in Greece, the effectiveness of meman-
tine was evaluated using the Mini-Mental State Examination (MMSE) and the Instrumental Ac-
tivities of Daily Living (IADL) scale at baseline, and after 3 and 6 months. Discontinuation rates 
and adverse drug reactions (ADRs) were also recorded to evaluate the safety profile of meman-
tine.  Results:  2,570 patients participated in the study. Three and 6 months after baseline, MMSE 
and IADL scores were significantly improved compared to baseline. At the end of the study, 67% 
of the patients had improved their MMSE score; 7.1% of the patients reported   6  1 ADRs, and 
treatment was discontinued due to ADR in 0.7%.   Conclusion:   Memantine was well tolerated 
and had a positive effect on the patient’s cognitive and functional ability in real-life clinical prac-
tice, in agreement with randomized, controlled trials.    Copyright © 2011 S. Karger AG, Basel 
  Published online: January 5, 2011
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 Introduction 
 Alzheimer’s disease (AD) is a progressive, extremely debilitating, neurodegenerative dis-
order, currently affecting almost 25 million people worldwide   [1]  . In 2002, the prevalence of 
dementia in Europe was estimated at 7 million individuals, and in most cases dementia was 
of the Alzheimer type   [2, 3]  . It is estimated that by 2050, the number of individuals living 
with dementia will increase by 161% in developed countries   [4]  . Due to its symptomatology, 
AD is strongly associated with a significant burden on patients, caregivers and the society in 
general   [5] .
  It has been well established that both the glutamatergic and the acetylcholinergic system 
work in synergy, contributing substantially to learning and memory, acquisition and retriev-
al   [6, 7]  . In particular, glutamate, the main excitatory neurotransmitter in the central ner-
vous system, is known to play a pivotal role in brain function, and thus memantine, a spe-
cific, moderate-affinity, uncompetitive N-methyl-  D  -aspartate (NMDA) receptor antagonist 
with strong voltage dependency and rapid blocking/unblocking kinetics   [8, 9]  , has been ap-
proved and prescribed for the treatment of moderate to severe AD.
    Treatment with memantine was associated with reduced clinical worsening in AD, 
based on an attempt to define marked clinical worsening as a decline of   6  4 points on the 
Alzheimer’s Disease Assessment Scale-Cognitive Subscale or   6  5 points on the Severe Im-
pairment Battery and any decline in the Clinician’s Interview-Based Impression of Change 
Plus Caregiver Input and the Alzheimer’s Disease Cooperative Study-Activities of Daily Liv-
ing Inventory   [10]  . Recently published reviews/meta-analyses of randomized controlled tri-
als (RCTs) with memantine treatment have shown that memantine reduces global, cognitive, 
and functional deterioration as well as the emergence of AD-associated behavioral changes 
compared with placebo   [11–16]  , and it is safe and well tolerated with an overall low rate of 
adverse effects   [17, 18]  .
    Although RCTs are undoubtedly the gold standard for drug evaluation, they do have 
certain limitations due to their strict inclusion/exclusion criteria, which may contribute to 
the underrepresentation of vulnerable patient groups   [19, 20]  . Thus, observational studies 
could in some cases be a valuable source of supplementary data reflecting the use of a me-
dicinal product in everyday clinical practice   [19–21]  . In the light of the above, the objective 
of the current observational study was to evaluate the effectiveness and tolerability of me-
mantine when used in routine clinical practice in a large outpatient population suffering 
from AD in Greece.
  M e t h o d s  
  In this open-label, multicenter, post-marketing observational study, AD patients were 
treated with memantine for 6 months. The study was conducted at 202 specialist sites. The 
patients were evaluated by psychiatrists and neurologists working for both the National 
Health Service, including 6 hospital outpatient units, and primarily private outpatient clinics 
in Greece.
  P a t i e n t s  
  No specific requirements were used for patient selection apart from the physician’s pos-
itive diagnosis of AD based on clinical criteria. Also, contraindications and safety measures 
listed in the summary of product characteristics of memantine had to be noted.12
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  Outcome  Measurements 
  The patients visited the clinic at the beginning of the study (baseline), and after 3 and 6 
months of memantine treatment. At baseline, demographic data and information on previ-
ous anti-AD treatment were collected. At all 3 visits, cognitive and functional performance 
was assessed using the Mini-Mental State Examination (MMSE)   [22]   and the Instrumental 
Activities of Daily Living (IADL)  [23]  scales, respectively. The IADL scale consists of 8 items: 
ability to use the telephone, shopping, food preparation, housekeeping, laundry, mode of 
transportation, responsibility for own medications, and the ability to handle finances. The 
scale is ranging from 8 to 31, where ‘31’ stands for total dependence and ‘8’ for full autonomy. 
Each subitem is scored independently, ranging from 1 to 3, 4 or 5, depending on the subitem. 
Whereas in most cases women are scored on all 8 subitems of function, the areas of food 
preparation, housekeeping, and laundry are excluded for most men (scoring 0 which stands 
for ‘not applicable’). In order not to exclude male patients, as has been done in other studies   
to avoid gender bias   [24]  , the IADL point score was converted into a percentage score with 
higher percentage scores indicating greater functional impairment. To define the specific 
instrumental activities in which functional improvement was detected over time, the per-
centage of patients showing total independency (scoring ‘1’ in the currently tested IADL 
subitem) and total dependency (scoring the highest mark in the currently tested IADL subi-
tem) was recorded for each IADL subitem. Compliance was assessed by the investigator at 
each visit. Concomitant medication was monitored continuously during the study. Safety 
and tolerability was assessed throughout the study by collection of spontaneously reported 
adverse drug reactions (ADRs). In the case of premature study discontinuation, the reason 
for withdrawal was ascertained at the next scheduled visit (3 or 6 months).
  Statistical  Analysis 
  Descriptive statistics were used for baseline demographics and clinical characteristics. 
Multiple linear regression (MLR) and the appropriate univariate test were used to evaluate 
the relationship of the baseline MMSE and IADL scores with age or education (Pearson’s 
correlation coefficient), sex or previous treatment (t test) and living conditions (ANOVA and 
Scheffé’s test).
    Analyses of MMSE and total IADL scores were performed for the intent-to-treat (ITT) 
population that included patients who had at least one evaluation after baseline and the per-
protocol set (PPS) that included patients who had evaluations at all visits. Repeated-measures 
analysis of variance (ANOVA; Hotelling’s test) and paired t test were used to test differences 
in MMSE and IADL scores between visits. Missing values were entered using MLR with the 
6-month score as dependent variable and the baseline/3-month score, age, and sex as inde-
pendent variables. Wilcoxon signed-rank test was used to evaluate differences in the patient’s 
ability to perform each single IADL item between the 1st and 3rd visits.
    Improvement in the MMSE scale was defined as any change   1  0 scores on the 2nd and 
3rd visits compared to baseline, stabilization as no change and worsening as any change   ! 0 
(values of the scale of visit 2 or 3, respectively, minus values of the scale obtained at baseline). 
Taking the progressive neurodegenerative profile of the disease into consideration, the per-
centage of clinical significant worsening based on MMSE scores was also calculated (MMSE 
difference in scores   6 3  points).
    Improvement in IADL scores was defined as any difference   !  0% between the 2nd and 
3rd visits compared to baseline, stabilization as no change and worsening as any change  1 0%.
    Descriptive statistics were used for safety and tolerability. MLR and the     2   test were ap-
plied to investigate the relationship of treatment discontinuation and ADRs with age, sex, 
education level, living conditions, previous acetylcholinesterase inhibitor (AChEI) treat-
ment, and current AD therapy.13
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  R e s u l t s  
  Baseline Demographics and Clinical Characteristics  
  In total, 2,570 patients participated in this study (  table 1  ). At baseline, mean age   8   SD 
was 74.8   8   6.8 years and mean baseline MMSE score was 18.0   8   5.2 (MMSE range: 2–26). 
Mean baseline IADL score was 69.1   8   20.0%. Of the AD patients, 1,690 (65.8%) had never 
received therapy for dementia prior to their inclusion into the study, while the remaining 
34.2% (880 patients) were already on AChEIs at baseline. During the study, 2,080 patients 
(80.9%) were given memantine as monotherapy, while 490 patients (19.1%) had combination 
therapy with AChEIs.
    Regression and univariate analyses showed that the baseline MMSE score was negative-
ly associated with age (MLR, Pearson correlation coefficient, r = –0.245, p   !   0.001), with 
older patients having lower baseline MMSE scores, being positively associated with educa-
tional level (MLR, Pearson correlation coefficient, r = 0.147, p   !   0.001), and less-educated 
patients having lower baseline MMSE scores. Patients living alone or with their spouse had 
the highest baseline MMSE score, while patients living in a home care setting had the lowest 
baseline MMSE compared to all other groups (MLR, ANOVA and Scheffé test, p  !  0.001, for 
both comparisons). The baseline IADL score was negatively correlated with the baseline 
MMSE score (MLR, Pearson correlation coefficient, r = –0.656, p  !  0.001) and positively cor-
Table 1.   Patient demographics and clinical characteristics
n%
Sex
Women 1,402 54.6
Men 1,168 45.4
Age
≤65 years 192 7.5
66–75 years 1,163 45.3
>75 years 1,215 47.3
Educational level
6 years 1,409 54.8
9 years 638 24.8
12 years 248 9.6
Diploma 123 4.8
University degree 152 5.9
Living conditions
Alone 263 10.2
With partner 1,337 52.0
With children, relatives, or others 893 34.7
In geriatric clinic 77 3.0
Baseline MMSE (score)
Mild dementia (>20) 1,095 42.6
Moderate dementia (10–19) 1,314 51.1
Severe dementia (<10) 161 6.3
Previous treatment with AChEIs
Yes 880 34.2
No 1,690 65.8
Current treatment
Memantine 2,080 80.9
Memantine + AChEIs for the duration of 
the study
490 19.114
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related with age (MLR, Pearson correlation coefficient, r = 0.329, p   !   0.001), with older pa-
tients having higher IADL scores and thus displaying less independency. Patients living 
alone had the lowest baseline IADL score compared to all other groups, and patients living 
with their spouse had lower baseline IADL scores than patients living with their children/
others or living in a home care setting (MLR, ANOVA and Scheffé test, p  !  0.001). Moreover, 
patients who had been treated with AChEIs previously had higher baseline IADL scores than 
untreated patients (MLR, t test, p   !   0.001).
  E f f e c t i v e n e s s  
 At 3 and 6 months, the MMSE score was significantly improved compared with the base-
line score for the ITT population (repeated-measures ANOVA Hotelling’s test, n = 2,442). 
The same results were obtained in the PPS population (repeated-measures ANOVA Hotell-
ing’s test, n = 2,093;   fig. 1  a). The paired-sample t test detected statistically significant differ-
ences in each of the three visit pairs (p   !   0.001 for all three pairs, 1st visit vs. 2nd visit, 2nd 
vs. 3rd visit, 1st vs. 3rd visit, for both ITT and PPS datasets). In the ITT population, 67.0% 
had improved their MMSE score, 18.6% had no change and 14.4% had worsening after 6 
  Fig. 1.   Mean MMSE and IADL scores with standard deviations for the ITT and PPS populations. Overall 
p value (Hotelling’s test): p   !   0.001; and baseline vs. 3 months, baseline vs. 6 months, and 3 vs. 6 months 
(paired t test): p   !   0.001. 15
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months of treatment; 112 patients (4.6%) experienced clinically significant worsening based 
on MMSE scores at the end of the study (decrease of   6  3 points). Similar results were ob-
served for the PPS population.
  The total IADL percentage score was significantly improved after 3 and 6 months of me-
mantine treatment both for the ITT (repeated-measures ANOVA Hotelling’s test, p   !   0.001, 
n = 1,859) and the PPS populations (repeated-measures ANOVA Hotelling’s test, p   !   0.001, 
n = 1,429;   fig. 1  b). The paired-sample t test detected statistically significant differences in 
each of the three visit pairs (p  !  0.001 for all three pairs, 1st vs. 2nd visit, 2nd vs. 3rd visit, 1st 
vs. 3rd visit, for both ITT and PPS datasets).
    Statistical analysis of single IADL items using the Wilcoxon signed-rank test showed a 
statistically significant improvement for each IADL item, comparing the ability of patients 
to perform any specific instrumental activity at baseline and after 6 months of memantine 
treatment (Wilcoxon signed-rank test, p   !   0.001, in all 8 IADL items).
  Safety  and  Tolerability 
  During the current study, 487 (18.9%) patients discontinued treatment (  table 2  ). The 
most common reason leading to the majority of treatment discontinuations was loss to fol-
low-up, while   !  1% patients enrolled discontinued due to ADRs (  table 2  ). The most common 
ADRs reported leading to treatment discontinuation were excitation (4 reports), somnolence 
(2 reports), constipation (2 reports), and nausea (2 reports).
    Multiple logistic regression analyses (stepwise method) showed that patients living with 
children/relatives (21.6 vs. 14.8% living alone, 18% living with spouse and 19.5% living in a 
care home; p   !   0.05), patients on monotherapy (21.1 vs. 9.8% for combination therapy; p   !  
0.001), and patients who had a higher baseline MMSE (21.7% in mild cases versus 16.9% in 
moderate cases and 16.8% in severe cases; p  !  0.01) were more likely to discontinue treatment.
  Of the 2,570 patients, 21 were lost to follow-up before the 3-month visit, and consequent-
ly the safety population consisted of 2,549 patients. One or more ADRs were reported by 182 
(7.1%) patients (  table 3  ). Dizziness and nausea were the most frequently reported ADRs, but 
still  ! 2% of the patients experienced either of these ADRs. ADRs of severe intensity occurred 
in 9 patients (0.35%): excitement (1 patient), bradycardia (1 patient, 2 reports), altered con-
sciousness (2 patients), agitation (1 patient), nausea and agitation (1 patient), hypotension (1 
patient), disinhibition (1 patient), and death (1 patient). According to the safety criteria, only 
2 cases were recorded as serious ADRs (bradycardia and death). The patient who died was a 
74-year-old man who developed oliguria and probably died because of acute renal failure. 
The patient had received memantine for almost 3 months. The patient’s medical history 
comprised diabetes mellitus, a common cause of renal disease, which could have contrib-
uted to the event. The temporal sequence does not support causality, and the investigator 
who reported the case did not think that the event was related to memantine treatment.
Table 2.   Withdrawal reasons
1st to 2nd visit 2nd to 3rd visit Total
Withdrawals, n (%) 140 (5.4) 347 (13.5) 487 (18.9)
Adverse events, n (%) 15 (0.6) 4 (0.1) 19 (0.7)
Treatment failure, n (%) 9 (0.4) 4 (0.1) 13 (0.5)
Loss to follow-up, n (%) 87 (3.4) 316 (12.3) 403 (15.7)
Patient’s/caregiver’s wish, n (%) 13 (0.5) 10 (0.4) 23 (0.9)
Other reasons, n (%) 16 (0.6) 13 (0.5) 29 (1.1)16
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  Discussion 
 Due to the extremely strict inclusion and exclusion criteria of RCTs, experimental design 
trials are sometimes unable to provide answers to a number of clinically important questions 
  [19, 20]  . The crucial difference between observational trials and RCTs is the absence of an 
experimental design. Thus, observational studies could be quite useful in studying already 
marketed pharmaceutical compounds in larger populations in comparison to RCTs, which 
may also include vulnerable patient groups   [20]  . Therefore, in the current open-label, post-
marketing, observational study, memantine treatment was studied in a heterogeneous, large 
population of patients suffering from AD in order to assess its effectiveness and tolerability 
profile in naturalistic settings. The exclusion criteria were meant to be as minimal as possi-
ble, restricted only to the absence of AD diagnosis, in order to represent everyday medical 
practice as realistically as possible. Furthermore, the inclusion criteria were widely defined 
in order to obtain a typical sample size representing AD patients undergoing pharmacolog-
ical treatment in real settings.
    As far as safety issues are concerned, the reported frequency of total ADRs, as well as 
those of severe intensity, was found to be in alignment with both the documented frequency 
in the summary of product characteristics of memantine as well as with the published data 
derived from other observational studies on memantine conducted in Austria and Germany 
  [25, 26]  . More specifically, in the German study, the ADR rate was   !  5%   [26]  ; in the Austrian 
4-month study, only 15.9% of patients reported an ADR   [25]  . The early discontinuation rate, 
which can be compared to the one from the Austrian study, was 18.9%. The main reason for 
discontinuation was loss to follow-up visits, which could be attributed to different reasons, 
e.g. lack of effectiveness or non-reported ADRs.
Table 3.   ADRs occurring in >1 patient
ADRs n %
Dizziness 37 1.44
Nausea 33 1.28
Headache 23 0.89
Excitement 20 0.78
Agitation 11 0.43
Somnolence 8 0.31
Gastrointestinal disorders 6 0.23
Constipation 6 0.23
Vomiting 5 0.19
Fatigue 5 0.19
Stomach ache 4 0.16
Imbalance 4 0.16
Diarrhea 4 0.16
Vertigo 3 0.12
Loss of appetite 3 0.12
Impaired consciousness 3 0.12
Sedation 3 0.12
Palpitations 2 0.08
Hypotonia 2 0.08
Insomnia 2 0.08
Tinnitus 2 0.08
Tremor 2 0.08
Dry mouth 2 0.0817
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    In accordance with already published clinical data as well as results from the aforemen-
tioned observational studies in other European countries   [25, 26]  , memantine therapy re-
sulted in statistically significant improvement or stabilization of the AD symptoms com-
pared to baseline. The MMSE score was significantly improved compared to the baseline 
score at the two follow-up visits (19.2   8   5.0 vs. 17.9   8   5.1, p   !   0.001, and 19.7   8   5.1 vs. 17.9 
  8  5.1, p  !  0.001, respectively, for the ITT population, and 19.1  8  5.0 vs. 17.8  8  5.1, p  !  0.001, 
and 19.6  8  5.1 vs. 17.8  8  5.1, p  !  0.001, respectively, for the PPS population). Moreover, 67% 
of the patients showed an improvement and 19% demonstrated no change in their MMSE 
score after 6 months of memantine treatment. This result is in agreement with the data for 
the MMSE score reported in the study by Calabrese et al.  [26] , in which 68.2% of the patients 
improved in the MMSE score by at least 1 point, and 9.6% remained stable at the end of the 
study period.
    Since AD is a progressive neurodegenerative disorder with no cure available to date and 
apart from symptom improvement the goal of AD treatment is the stabilization of the pa-
tient’s condition, it was considered meaningful to calculate the percentage of patients expe-
riencing significant clinical worsening at the end of the current 6-month study. In previ-
ously published reports based on the MMSE scale – a scale which has been broadly applied 
to evaluate the patients’ cognitive symptoms and their severity evolution – it has been calcu-
lated that a patient receiving no treatment for dementia should lose approximately 3 points 
in the MMSE in 6 months   [27]  .
    Considering all the above, only 4.6% of the patients experienced clinically significant 
worsening based on MMSE scores at the end of the study.
    Using the 8-item IADL scale allowing the assessment of changes in one’s dependency 
over time, statistically significant improvement in IADL compared to baseline was reported 
for both the IADL score recorded as percentage as well as the single-item ADL analyses con-
ducted at the end of the 6-month memantine treatment. More specifically, the IADL score 
was significantly improved compared to the baseline score (with lower scoring at the two 
follow-up visits, 66.0   8   19.7 vs. 68.9   8   20.1, p   !   0.001, and 64.3   8   19.6 vs. 68.9   8   20.1, p   !  
0.001, respectively, for the ITT population and 66.6   8   19.5 vs. 69.5   8   20.0, p   !   0.001, and 
64.8   8   19.7 vs. 69.5   8   20.0, p   !   0.001, respectively, for the PPS population), showing less 
dependency in functional activities over time. In order to define the specific instrumental 
activities in which functional improvement was detected over time, the percentage of pa-
tients showing total independency and total dependency was recorded for each IADL subi-
tem. It was evident that improvement was statistically significant in all eight instrumental 
activities evaluated by the IADL scale, with an increase in the percentage of patients able to 
perform each activity independently at each follow-up visit.
    The present results concerning the functional ability of AD patients are in agreement 
with results from single-item ADL analyses  [28]  demonstrating the positive effect of meman-
tine treatment on the maintenance or even improvement in the level of independency regard-
ing daily activities such as shopping and food preparation. In other post-marketing studies 
  [26]  , functional performance was also improved after a 6-month memantine treatment, al-
though other scales were selected to evaluate activities of daily living (e.g. NOSGER – Nurs-
es Observation Scale for Geriatric Patients). However, at a closer look, the improvement in 
the subscale of NOSGER in the observational study by Calabrese et al.  [26]  was in agreement 
with the current results, although their patients were at a more severe AD stage at baseline 
than the patients in the current study.
    The results of this observational study should be seen and discussed after taking spe-
cific limitations into consideration. Besides the limitations of observational studies in gen-
eral, mainly due to the absence of randomization and the lack of predefined endpoints, in 
the current study, the percentage of patients lost to follow-up visits was high. Most likely, this 18
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is due to the absence of close monitoring, which is applied in RCTs. The high percentage of 
patients lost to follow-up may have different reasons, including lack of effectiveness, disease 
progression, or occurrence of ADRs. Moreover, the Lawton IADL scale is not the most ap-
propriate tool to evaluate response to dementia treatment and functional changes over time. 
However, the need for an easy-to-use and quickly administered scale led us to the decision 
to include it in the case report form of the observational study.
  Conclusion 
  The results of this observational study in naturalistic settings support the outcomes 
demonstrated in RCTs of AD patients receiving memantine as treatment for dementia com-
pared to placebo-treated patients, with 67% of the patients showing an improvement in their 
MMSE score at the end of the study and only 7.1% of patients reporting  6 1 ADR throughout 
the study. The current results also seem to be in alignment with published results from oth-
er observational studies conducted in large AD patient cohorts treated with memantine.
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